A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Lymphoma
  • Age: Between 18 Year(s) - 79 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1) Subject has no history of prior systemic anti-lymphoma therapy for DLBCL (including any definitive radiotherapy with curative intent) other than corticosteroids with or without vincristine during prephase treatment, or non-curative intent palliative radiotherapy with the stipulation that radiated lesions cannot be selected as target lesion for response assessment
    2. 2) Subject is planned to receive treatment with 6 cycles of standard R-CHOP
    3. 3) Subject must have newly diagnosed, histologically confirmed CD20+ DLBCL

You may not be eligible for this study if the following are true:

    1. 1) Has history of primary mediastinal lymphoma, or mediastinal or pericardial radiation
    2. 2) Has a primary CNS tumor or known CNS involvement at Screening
    3. 3) Has clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.